1. The use of 5- (2,6-dimorpholin-4-yl-pyrimidin-4-yl) -4-trifluoromethyl-pyridin-2-ylamine or its stereoisomer, tatomer or pharmaceutically acceptable salt to obtain a pharmaceutical composition for the treatment of VEGF-stimulated angiogenic disease. 2. The use according to claim 1, where the disease to be treated is rheumatoid arthritis, synovitis, destruction of bones and cartilage, osteomyelitis, proliferation of pannus, the formation of osteophytes, hepatitis, premium, glomerulonephritis, asthma, nasal polyps, transplantation, formation in the liver, retinopathy of premature age, macular degeneration, diabetic retinopathy, choriodal and other intraocular diseases, leukomalacia, thyroiditis, thyroid hypertrophy, lymphoproliferative diseases, Kaposi’s sarcoma, hematological Malignant disease (e.g., haemangiomas), obesity, spinal cord injury, acute myocardial infarction, pulmonary edema, brain, retina, or any kombinatsiy.3. The use according to claim 1, wherein the compound is administered in combination with a VEGF or VEGFR targeted agent selected from the group consisting of bevacizumab, anti-VEGF, ranibizumab, AVE0005, anti-VEGF HuMV833, anti-VEGF 2C3, anti-VEGF CBO-P11 , sutent, sorafenib, vatalanib, zaktima, midostaurin, angzima, AG-013736, stelautinib, CP-547,632, CEP-7055, KRN633, NVP-AEE788, IMC-1211, ZK260253, semaxaniba, E-7107, AS-3, Cand and PTC-299 and HSP90 inhibitors CNF1010, CNF2024, Tanespimycin, Alvespimycin, IPI504, SNX5422 and NVP-AUY922, where the active ingredients are present in each case in free form or in the form of a pharmaceutically acceptable salt. 4. A method of treating a VEGF-stimulated angiogenic disease comprising administering a therapeutically effective amount of 5- (1. Применение 5-(2,6-диморфолин-4-ил-пиримидин-4-ил)-4-трифторметил-пиридин-2-иламина или его стереоизомера, татомера или фармацевтически приемлемой соли для получения фармацевтического состава для лечения VEGF-стимулированного ангиогенного заболевания.2. Применени
